Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
about
Biosimilars: the need, the challenge, the future: the FDA perspectiveEpoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Regulatory and clinical considerations for biosimilar oncology drugsCharacterization and comparison of commercially available TNF receptor 2-Fc fusion protein productsBiosimilars: Current regulatory perspective and challenges.Biosimilars: Still Not Quite Ready for Prime Time.Developing top down proteomics to maximize proteome and sequence coverage from cells and tissues.Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.Biosimilars advancements: Moving on to the future.State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.Windows of opportunities and technological innovation in the Brazilian pharmaceutical industry.Trace element associated reduction of norleucine and norvaline accumulation during oxygen limitation in a recombinant Escherichia coli fermentation.Simultaneous analysis of the non-canonical amino acids norleucine and norvaline in biopharmaceutical-related fermentation processes by a new ultra-high performance liquid chromatography approachBiologics and biosimilars.Enhanced expression of a biosimilar monoclonal antibody with a novel NS0 platform.The process defines the product: what really matters in biosimilar design and production?Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Quantification of recombinant human erythropoietin by amino acid analysis using isotope dilution liquid chromatography-tandem mass spectrometry.Laboratory Medicine to improve biological therapeutic treatment
P2860
Q28242669-65510942-0065-4643-A339-4801F0EFFFF1Q35162053-51813AA3-7C26-4927-A0B9-51AA88365FF7Q35505833-2C6FEC8D-1530-43BF-8F5B-0A221B600464Q36411858-5BC3801B-456E-408A-AEA2-4097B2FD9006Q36728729-79AEE7E8-3551-4F9E-B59B-C5CEF83EF5FBQ36972833-21777029-C162-469E-8EFF-A27C172C0FBCQ37426025-9C621BCC-29EA-42ED-AF1A-D97DFB49CD71Q38059422-4220437C-56DB-4F17-943B-E8D6A3E0455CQ38364577-09E7DD8A-F3EB-44CE-8CC6-1BA06C536234Q38556990-4A691344-0303-4EAB-9A63-90664EFB27AEQ38591241-859E8573-7842-439C-91AB-C7E586AE9C0EQ38591272-3902E53D-86CB-48AB-B025-D57FA005362CQ38641699-C951D076-126B-4E2D-A4C8-079E1EAC42A8Q38763700-56D000BA-D867-4714-A32C-7FDFC3E40730Q39201672-101130BE-98A5-4024-B7F9-03340C9DA477Q39310578-EC3B5499-19D4-4347-A38C-CE3AD98AFB6CQ39488041-7EA7C3AE-1E17-4490-93A0-EF7F09947FDFQ40805412-EE358410-33E0-4694-9177-1CF314F397BDQ48324789-FFD2A49A-69A9-4DAE-B660-6D5B4F96A821Q50115805-F96B608C-7348-484A-8FC2-71617F62D4A0Q52651099-F40AEC8A-6260-41C4-A458-9DCFF44593A7Q53280427-FF45A8A6-195B-4875-A9C0-45B1AA0E7A87Q58055739-7075FEB8-16F8-47BC-827D-ED1641C1A77B
P2860
Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biosimilars: impact of biologi ...... ajectory in the United States.
@en
Biosimilars: impact of biologi ...... ajectory in the United States.
@nl
type
label
Biosimilars: impact of biologi ...... ajectory in the United States.
@en
Biosimilars: impact of biologi ...... ajectory in the United States.
@nl
prefLabel
Biosimilars: impact of biologi ...... ajectory in the United States.
@en
Biosimilars: impact of biologi ...... ajectory in the United States.
@nl
P2093
P1476
Biosimilars: impact of biologi ...... ajectory in the United States.
@en
P2093
Ben Kaspar
Islah Ahmed
Uma Sharma
P304
P356
10.1016/J.CLINTHERA.2011.12.005
P577
2012-01-13T00:00:00Z